Type 2 Diabetes

Announced on Feb. 18, the t:connect mobile app, which pairs with the t:slim X2 insulin pump, is the first-ever FDA-cleared smartphone application capable of initiating insulin delivery on both iOS and Android operating systems, according to Tandem Diabetes Care.

More than 1-in-3 patients with T2D and ASCVD in a large cohort were receiving none of the 3 evidence-based therapies associated with significant cardiovascular benefit, including lipid-, blood pressure-, and glucose-lowering pharmacotherapy.

Diana Isaacs, PharmD, provides insight and perspective into the current state of the fight against diabetes after a recent CDC report provides data demonstrating the death toll attributable to diabetes reached 100,000 in 2021.

Higher variability of adiposity indices was associated with significantly increased risk of CVD outcomes in standard of care, but not in the intensive lifestyle intervention group.

A retrospective cohort study suggests users of DOACs were at a 16% lower risk of developing macrovascular complications, a 21% lower risk of microvascular complications, and a 22% lower risk of mortality compared with warfarin users among a population of patients with diabetes and atrial fibrillation.

Data show fewer than 1 in 20 patients with diabetes and ASCVD were prescribed a high-intensity statin, either an ACEI or ARB, and either an SGLT2I and/or a GLP-1RA.

The percentage of time with glucose level in the target range was 8.7 percentage points higher during the closed-loop period compared to control.

Results of a randomized, crossover trial indicate closed-loop control could improve glucose control versus standard insulin therapy in patients with type 2 diabetes requiring dialysis.

An economic evaluation using a microsimulation model comparing Roux-en-Y gastric bypass, sleeve gastrectomy, and medical therapy for severe obesity in patients with type 2 diabetes suggests gastric bypass was the most cost-effective approach.

A systematic review and meta-analysis suggest approximately 20% of girls with type 2 diabetes also had polycystic ovary syndrome.

Data from a national research database in Taiwan provides insight into the apparent reductions in risk associated with DOAC use compared to warfarin in patients with atrial fibrillation and diabetes.

A new set of guidelines endorsed by the American Limb Preservation Society underline the importance of nutrition in the management of diabetic foot ulcers.

Announced on February 11, the approval for Eversense E3 continuous glucose monitoring system allows access to a CGM system with 6 months of longevity and is expected to be available beginning in the second quarter of 2022.

AN analysis of the UK Biobank cohort provides insight into the increased risk of cardiovascular disease associated with gestational diabetes, including a 69% increase in risk of stroke and 42% increase in risk of heart failure later in life.

New guidelines recommend healthcare providers develop and implement an individualized nutrition care plan for individuals with diabetes with or at risk of a DFU.

A higher percentages of patients treated with tirzepatide had HbA1c less than 7% versus those treated with placebo (85%-90% versus 34%).

Data from the SURPASS-5 trial demonstrate the safety and efficacy of multiple tirzepatide doses as an add-on therapy to titrated insulin glargine for glycemic control and weight loss in patients with type 2 diabetes.

A recent analysis of data is providing insight into the use of aspirin for preeclampsia prevention among women with prepregnancy obesity, hypertension, or diabetes.

Comparing SGLT2 inhibitor and GLP-1 RA use versus DPP-4 inhibitors in patients with type 2 diabetes, investigators found use of newer glycemic agents could provide protection against NAFLD in addition to their cardiorenal protective benefits.

Cardiovascular disease is the leading cause of death for women.

Rates of aspirin use for preeclampsia prophylaxis were observed in a minority of women with risk factors including pre-pregnancy diabetes, obesity, or chronic hypertension.

Announced on Jan. 28, the Omnipod 5 AID becomes the first tubeless automated insulin delivery system with the ability to integrate with the Dexcom G6 continuous glucose Monitoring System and a compatible smartphone to automatically adjust insulin and protect against glycemic events

An analysis of data from the Normative Aging Study provides insight into associations of neuroticism and worry with risk of cardiometabolic disorders in men over a 40-year period.

There was not an association between sleep duration and metabolic diseases found in men.

An analysis of data from more than 135k patients with type 1 and type 2 diabetes indicates the age-adjusted rate of chronic kidney disease was greater in type 1 diabetes and also sheds light on the rising rate of obesity in type 1 diabetes.